Lamisil, Terbinafine Wire
Comprehensive News Feed for Lamisil, Terbinafine (generic).
Results 1 - 20 of 23 in Lamisil, Terbinafine (generic)
-
NexMed Granted Continued Listing on NASDAQ
NexMed, Inc. , a specialty CRO and a developer of products based on the NexACT technology, today announced that it received a letter from the NASDAQ Listing Qualifications Panel on December 17, 2009, informing the Company that the Panel had granted the Company's request to remain listed on the NASDAQ Stock Market, subject to the condition that, on ... Comment?
-
NexMed, Inc. Leases Its Facility in New Jersey
NexMed, Inc. , a specialty CRO and a developer of products based on the NexACT technology, today announced that it has signed an agreement to lease its facility in East Windsor, NJ, commencing February 1, 2010. Comment?
-
Hospira buys Orchid unit for $400 mn
Cos sign pact for supply of pharma ingredients. US-based drug major Hospira will buy the injectable pharmaceuticals business of Chennai-based Orchid Chemicals for $400 million . Comment?
-
NexMed Closes Acquisition of Bio-Quant
NexMed, Inc. , a developer of products based on the NexACT technology, today announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Comment?
-
Emerging Stock Report Initiates Independent Research Coverage on NexMed, Inc.
Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on NexMed, Inc. Comment?
-
NexMed, Inc. to Acquire Bio-Quant, Inc.
Nov 23, 2009 - NexMed, Inc. , a developer of products based on the NexACT technology, today announced that it has entered into a definitive agreement to acquire Bio-Quant, Inc., a revenue generating privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in ... Comment?
-
Toe nail fungus among us
w/Photo
By age 70, nearly half of all Americans will have one or more toes infected with toenail fungus . Comment?
-
NexMed to Acquire Bio-Quant, Inc.
NexMed, Inc. , a developer of products based on the NexACT technology, today announced that it has entered into a definitive agreement to acquire Bio-Quant, Inc., a revenue generating privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Comment?
-
NexMed Receives Cash Infusion of $750,000
NexMed, Inc. , a developer of innovative transdermal products based on the NexACT drug delivery technology, today announced that it raised $750,000 in gross proceeds from the issuance of new convertible notes due December 31, 2011 , which are secured by a mortgage on NexMed's facility in East Windsor, New Jersey. Comment?
-
NexMed Announces Third Quarter 2009 Financial Results Conference Call
NexMed, Inc. , a developer of innovative topical products based on the NexACT technology, today announced that management will hold a conference call to discuss 2009 third quarter financial results and ongoing corporate activities, on Tuesday, November 10, 2009 at 10:00 a.m. EST. Comment?
-
NexMed Confirms Nasdaq Hearing Date
NexMed, Inc. , a developer of products based on the NexACT technology, today announced that it has heard back from the Nasdaq Listing Qualifications Department regarding its request for a hearing concerning its possible delisting from the Nasdaq Capital Market, and that a hearing has been scheduled for Thursday, November 12, 2009. Comment?
-
NexMed Provides Update on Anti-Fungal Product
NexMed, Inc. , a developer of products based on the NexACT technology, today announced that it has completed its post hoc analysis of NM100060, the Company's topically-applied treatment for onychomycosis, commonly known as nail fungus. Comment?
-
NexMed Provides Update on Anti-Fungal Product; Seeks Partner for Further Development
NexMed, Inc., a developer of products based on the NexACTA technology, today announced that it has completed its post hoc analysis of NM100060, the Companya s topically-applied treatment for onychomycosis, commonly known as nail fungus. Comment?
-
Nail bed disease: Alcohol-based solutions help distal subungual onychomycosis
w/Photo
Dermatologists should consider the use of alcohol-based topicals for the treatment of distal subungual nail bed disease, says Joseph Bikowski, M.D., director of the Bikowski Skin Care Center in Sewickley, Pa. Comment?
-
THEY'VE survived catastrophe on the flume of death at your holiday resort, avoided being burnt to a crisp on those days when the sun finally broke through the rain, and managed to avoid shattering any bones skateboarding and trampolining. Comment?
-
Bed of nails: Nanoemulsion provides unique platform for topical treatment of onychomycosis
Findings from studies of a novel nanoemulsion technology indicate it has exciting potential to enable safe and effective topical treatment of onychomycosis. Comment?
-
NexMed Submits Compliance Plan to Nasdaq
NexMed, Inc. , a developer of innovative topical products based on the NexACT technology, today announced that it has submitted to Nasdaq its plan to achieve and sustain compliance with Marketplace Rule 4310 . Comment?
-
NexMed Receives Nasdaq Delisting Warning Letter
Aug 14, 2009 - NexMed, Inc. , a developer of innovative topical products based on the NexACT technology, today announced that it has received a notice from Nasdaq indicating that it does not comply with the minimum $2.5 million in stockholders' equity requirement for continued listing on the Nasdaq Capital Market set forth in Marketplace Rule 4310 ... Comment?
-
NexMed Receives Nasdaq Delisting Warning Letter
NexMed, Inc. , a developer of innovative topical products based on the NexACT A technology, today announced that it has received a notice from Nasdaq indicating that it does not comply with the minimum $2.5 million in stockholdersa equity requirement for continued listing on the Nasdaq Capital Market set forth in Marketplace Rule 4310 . Comment?
-
Ibutilide controlled studies suicidality. Bp of lamisil generic to inform patients diminish. Comment?
Lamisil, Terbinafine Forum
Most Popular
- U.S. Democrats secure 60th vote on health bill - 538 comments
- DC Mom Files Complaint Against Lesbian Teacher for Corrupting Child's Innocence - 480 comments
- Zizie Ezette & Bung Mokhtar Dikatakan Berkahwin Tapi Bung Nafi - 195 comments
- Shame On Me For Voting For Obama - 89 comments
- Plainclothes Cop Pulls Gun At Snowball Fight - 59 comments
- A bleak future for black children and youth - 127 comments
- DC Marriage Equality Law Signed - 129 comments
- Russia condemns demolition of WWII memorial in Georgia - 216 comments
- TV talent show exposes China's race issue - 46 comments
- Florida-Based Company To Bring 1,400 Jobs To Clay County - 27 comments
|
Reach local customers. Engage a specific demographic. Maximize business-to-business opportunities. Topix can deliver your message.
|
Copyright ©2009 Topix LLC
